Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 10/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. ARWR, ACLX, PCVX, KYMR, PTGX, CRNX, ZLAB, AKRO, MIRM, and AAPGShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Arrowhead Pharmaceuticals Arcellx Vaxcyte Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics Mirum Pharmaceuticals Ascentage Pharma Group International Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Which has more volatility and risk, CALT or ARWR? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Do analysts prefer CALT or ARWR? Arrowhead Pharmaceuticals has a consensus target price of $43.14, indicating a potential upside of 18.07%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78 Do insiders and institutionals have more ownership in CALT or ARWR? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer CALT or ARWR? In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Arrowhead Pharmaceuticals' average media sentiment score of 0.48 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Arrowhead Pharmaceuticals Neutral Which has better valuation & earnings, CALT or ARWR? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Arrowhead Pharmaceuticals$3.55M1,423.10-$599.49M-$1.28-28.55 Is CALT or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Arrowhead Pharmaceuticals' return on equity of -40.91% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Arrowhead Pharmaceuticals N/A -40.91%-11.62% SummaryArrowhead Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$805.10M$6.12B$10.65BDividend YieldN/A4.84%5.70%4.74%P/E Ratio-21.621.2585.6626.85Price / Sales0.7429.47622.88135.13Price / CashN/A17.6437.7861.77Price / Book37.747.6513.216.70Net Income-$43.96M-$7.66M$3.30B$276.44M7 Day PerformanceN/A29.29%3.95%2.48%1 Month PerformanceN/A32.32%8.40%8.79%1 Year PerformanceN/A66.52%88.36%34.41% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ARWRArrowhead Pharmaceuticals3.9943 of 5 stars$34.17+1.1%$43.14+26.3%+101.5%$4.72B$572.98M-26.70400ACLXArcellx2.2336 of 5 stars$82.48+4.3%$114.31+38.6%+12.0%$4.57B$56.98M-24.1280PCVXVaxcyte2.4428 of 5 stars$35.22+1.6%$106.25+201.7%-61.4%$4.57BN/A-8.57160KYMRKymera Therapeutics1.9016 of 5 stars$58.03-0.8%$60.74+4.7%+34.8%$4.18B$47.07M-16.84170PTGXProtagonist Therapeutics2.1133 of 5 stars$66.53+2.1%$68.36+2.8%+49.5%$4.14B$434.43M95.04120Positive NewsAnalyst ForecastCRNXCrinetics Pharmaceuticals3.8879 of 5 stars$42.06-3.3%$74.45+77.0%-17.9%$3.96B$1.04M-10.22210ZLABZai Lab2.8351 of 5 stars$34.16+3.7%$56.35+65.0%+24.8%$3.82B$398.99M-16.751,869AKROAkero Therapeutics3.6972 of 5 stars$47.28-0.7%$81.14+71.6%+72.0%$3.78BN/A-23.6430MIRMMirum Pharmaceuticals3.4564 of 5 stars$74.74+2.6%$76.50+2.4%+90.3%$3.75B$336.89M-61.76140Positive NewsAAPGAscentage Pharma Group InternationalN/A$39.79+3.2%N/AN/A$3.71B$134.35M0.00600News Coverage Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Vaxcyte Alternatives Kymera Therapeutics Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives Mirum Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
